A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This is a pilot study, assessing the feasibility, safety and toxicity of an mTOR (mammalian
target of Rapamycin) inhibitor (MTI), rapamycin, when administered with HyperCVAD
(Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicine and Dexamethasone), with an
ultimate goal to perform a phase II study to evaluate response rates and survival in adults
with Acute Lymphoblastic Leukemia (ALL) and aggressive lymphoid malignancies.
Phase:
Early Phase 1
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University